Acumen Pharmaceuticals (ABOS)

• Market cap: $80M
• 1 day: -5.04%
• 5 days: -10.2%
• 1 month: 4.76%
• 3 months: 15.79%
• 6 months: 3.13%
• Year to date: -28.65%
• 1 year: -46.12%
• 5 years: -93.43%
• 10 years: -93.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,200% more call options, than puts

Call options by funds: $46K | Put options by funds: $2K

3% less capital invested

Capital invested by funds: $44.8M [Q1] → $43.6M (-$1.16M) [Q2]

4.88% less ownership

Funds ownership: 66.97% [Q1] → 62.09% (-4.88%) [Q2]

13% less funds holding

Funds holding: 80 [Q1] → 70 (-10) [Q2]

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

37% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 27

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $6.5
• High target: $9

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Geoff Meacham	$9	Buy Maintained	25 Aug 2025
Citigroup Geoff Meacham	$4	Buy Initiated	17 Jun 2025